Programmable Delivery of Synergistic Cancer Drug Combinations Using Bicompartmental Nanoparticles
Jason V Gregory1, Douglas R Vogus2, Alexandra Barajas3
1Biointerfaces Institute and Department of Chemical Engineering, University of Michigan, Ann Arbor, MI, 48109, USA.
Abstract:
Delivery of multiple therapeutics has become a preferred method of treating cancer, albeit differences in the biodistribution and pharmacokinetic profiles of individual drugs pose challenges in effectively delivering synergistic drug combinations to and at the tumor site. Here, bicompartmental Janus nanoparticles comprised of domains are reported with distinct bulk properties that allow for independent drug loading and release. Programmable drug release can be triggered by a change in the pH value and depends upon the bulk properties of the polymers used in the respective compartments, rather than the molecular structures of the active agents. Bicompartmental nanoparticles delivering a synergistic combination of lapatinib and paclitaxel result in increased activity against HER2+ breast cancer cells. Surprisingly, the dual drug loaded particles also show significant efficacy toward triple negative breast cancer, even though this cancer model is unresponsive to lapatinib alone. The broad versatility of the nanoparticle platform allows for rapid exploration of a wide range of drug combinations where both their relative drug ratios and temporal release profiles can be optimized.
Insights
Novel Janus nanoparticles enable precise delivery of multiple cancer drugs, overcoming biodistribution challenges. This platform enhances synergistic drug combinations for improved cancer treatment efficacy.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Delivering multiple therapeutics for cancer treatment is challenging due to varying drug biodistribution and pharmacokinetics.
- Achieving synergistic drug combinations at the tumor site requires advanced delivery systems.
Purpose of the Study:
- To develop bicompartmental Janus nanoparticles for independent loading and release of multiple therapeutics.
- To investigate the efficacy of these nanoparticles in delivering synergistic drug combinations for cancer treatment.
Main Methods:
- Fabrication of bicompartmental Janus nanoparticles with distinct polymer domains for independent drug encapsulation.
- Utilizing pH-triggered release mechanisms dependent on polymer properties for programmable drug delivery.
- Evaluating the in vitro efficacy of dual-drug loaded nanoparticles against HER2+ and triple-negative breast cancer cells.
Main Results:
- Bicompartmental nanoparticles successfully achieved independent loading and pH-triggered release of drugs.
- Dual-drug loaded nanoparticles demonstrated enhanced activity against HER2+ breast cancer cells.
- Surprisingly, the nanoparticles also showed significant efficacy against triple-negative breast cancer, which is typically unresponsive to single agents.
Conclusions:
- The developed Janus nanoparticle platform offers a versatile approach for optimizing synergistic drug combinations and release profiles.
- This technology has the potential to broaden therapeutic options for various cancer types, including those resistant to conventional treatments.
More Related Videos
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...